NCT07208786 Pre-emptive Endoscopic Vacuum Therapy Reduces the Incidence of Anastomotic Leakage After Colorectal Cancer Surgery
| NCT ID | NCT07208786 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nanchong Central Hospital |
| Condition | Colorectal Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 110 participants |
| Start Date | 2025-09-22 |
| Primary Completion | 2026-10-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 110 participants in total. It began in 2025-09-22 with a primary completion date of 2026-10-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Evaluate the safety and efficacy of postoperative Pre-emptive EVT (PEVT) in reducing the incidence of anastomotic leaks within 30 days after surgery in patients with colorectal cancer. Compare the differences between the PEVT group and the control group in terms of operation time, length of hospital stay, and total medical costs. Analyze the incidence of other postoperative complications in the two groups, such as wound infection, abdominal abscess, and intestinal obstruction. Assess the impact of PEVT on postoperative recovery indicators, including time to first flatus, time to first defecation, and time to ambulation. Observe the occurrence of PEVT-related adverse events, such as device displacement, bleeding, and infection.
Eligibility Criteria
Inclusion Criteria: 1. Pathologically diagnosed with colorectal cancer, planned for radical surgery (right hemicolectomy, left hemicolectomy, or anterior resection of the rectum, etc.). 2. Age 18-85 years, American Society of Anesthesiologists (ASA) classification I-III. 3. Anastomosis to be performed in a single stage (meeting anastomotic criteria). 4. Patient or legal guardian is able to understand and sign the informed consent form and comply with follow-up. Exclusion Criteria: 1. Preexisting anastomotic leakage or severe intra-abdominal infection before surgery. 2. Complicated by severe cardiovascular or cerebrovascular diseases (e.g., acute myocardial infarction, acute phase of cerebral infarction). 3. Severe liver or kidney dysfunction (liver function Child-Pugh class C, creatinine clearance \<30 ml/min). 4. Coagulation disorders (platelets \<50×10⁹/L, INR \>1.5) or receiving anticoagulant therapy that cannot be adjusted. 5. History of abdominal radiotherapy or multiple abdominal surgeries leading to severe intra-abdominal adhesions. 6. Complicated by other malignant tumors and currently undergoing radiotherapy or chemotherapy. 7. Psychiatric illness or cognitive impairment preventing compliance with the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07208786 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07208786 currently recruiting?
Yes, NCT07208786 is actively recruiting participants. Contact the research team at drtianyunhong@126.com for enrollment information.
Where is the NCT07208786 trial being conducted?
This trial is being conducted at Nanchong, China.
Who is sponsoring the NCT07208786 clinical trial?
NCT07208786 is sponsored by Nanchong Central Hospital. The trial plans to enroll 110 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.